Trulicity vs Retatrutide: Switching Between Them

What Are These Two Drugs and How Do They Differ?

Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist approved by the FDA in September 2014 for type 2 diabetes management and, since 2020, for cardiovascular risk reduction in adults with established cardiovascular disease or multiple risk factors. Retatrutide is a once-weekly triple receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously, placing it in an entirely different pharmacological class despite sharing the weekly subcutaneous injection format.

Mechanism of Action: One Receptor vs. Three

Dulaglutide binds selectively to the GLP-1 receptor, stimulating glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite through central nervous system pathways. The FDA prescribing information for dulaglutide confirms its half-life of approximately 5 days, which supports once-weekly dosing.

Retatrutide adds two additional receptor targets. GIP receptor activation augments insulin secretion and may directly promote fat-cell lipolysis. Glucagon receptor activation increases hepatic glucose output (an effect that retatrutide's GLP-1 component counters) and, at the systemic level, raises energy expenditure by stimulating brown adipose tissue thermogenesis. The net result is a caloric-output increase that no single GLP-1 agonist achieves. This triple mechanism is the primary reason Phase 2 data showed weight loss nearly six times larger than typical dulaglutide outcomes.

Approved Indications vs. Investigational Status

This distinction matters for prescribing and insurance coverage. Dulaglutide carries two FDA indications: glycemic control in type 2 diabetes and reduction of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors, per the 2020 label update. The FDA's accessdata portal documents both indications.

Retatrutide has no FDA-approved indication as of mid-2024. Eli Lilly initiated Phase 3 trials in 2023, but the drug remains investigational. Patients cannot obtain it through standard pharmacy channels, and prescribers cannot legally write a commercial prescription for it in the United States.

Efficacy Data: What the Trials Actually Show

The efficacy gap between these two agents is large, but the comparison is not straightforward because the trials studied different populations, used different endpoints, and occurred at different stages of drug development.

Dulaglutide in REWIND

REWIND (Researching Cardiovascular Events With a Weekly Incretin in Diabetes) enrolled 9,901 adults with type 2 diabetes across 24 countries and followed them for a median of 5.4 years. Dulaglutide 1.5 mg once weekly reduced the primary composite MACE endpoint (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) by 12% relative to placebo (HR 0.88; 95% CI 0.79 to 0.99; P<0.026) [1]. That cardiovascular benefit is the most clinically meaningful outcome in any long-duration outcomes trial for a GLP-1 agent and sets dulaglutide apart from agents that have only short-term efficacy data.

Weight loss in REWIND was modest. Mean body-weight reduction was approximately 3 kg over the trial duration in the dulaglutide group. The AWARD-11 trial, which studied the higher 4.5 mg dose, reported 3.1 kg greater weight reduction versus placebo at 52 weeks [2]. These numbers confirm dulaglutide as a glucose-lowering and cardioprotective drug that produces incidental weight loss rather than a dedicated anti-obesity agent.

Retatrutide Phase 2: Jastreboff et al. (NEJM 2023)

The Phase 2 dose-ranging trial published by Jastreboff et al. In the New England Journal of Medicine enrolled 338 adults with obesity (BMI 30 or higher) without type 2 diabetes and randomized them to retatrutide doses of 1 mg, 4 mg, 8 mg, or 12 mg once weekly or placebo for 48 weeks [3]. At the 12 mg dose, participants lost a mean of 24.2% of body weight at 48 weeks. The 8 mg dose produced 17.3% mean weight loss. Placebo participants lost 2.1%. All active doses achieved statistical significance versus placebo (P<0.001 for all comparisons) [3].

These figures exceed every GLP-1 monotherapy published to date, including semaglutide 2.4 mg (Wegovy), which produced 14.9% mean weight loss at 68 weeks in STEP-1 (N=1,961) [4]. The Jastreboff trial did not include a cardiovascular outcomes endpoint, so no MACE data exist for retatrutide. Phase 3 trials are designed to generate that data.

Side-Effect Profiles: Largely Overlapping, Some Differences

Both drugs share the GLP-1 class side-effect signature: nausea, vomiting, diarrhea, constipation, and decreased appetite, predominantly during the titration phase. In the Jastreboff Phase 2 trial, nausea occurred in 45% of participants at 12 mg versus 17% in the placebo group [3]. Dulaglutide's prescribing information reports nausea in approximately 12 to 21% of patients across its approved dose range [FDA label]. The higher nausea incidence with retatrutide likely reflects the more aggressive weight-loss signal and the additional glucagon receptor activity.

Injection-site reactions, pancreatitis risk, and the theoretical thyroid C-cell concern (observed in rodents at pharmacological doses and carried as a class warning) apply to both. Retatrutide's glucagon receptor agonism introduces an additional theoretical hepatic glucose risk if the GLP-1 counterbalance is insufficient, though this was not clinically significant in Phase 2 at approved titration schedules.

Direct Head-to-Head Data: Does It Exist?

No published randomized controlled trial has directly compared dulaglutide and retatrutide in the same population using the same endpoints. Every number cited above comes from separate trials with different inclusion criteria, different follow-up durations, and different primary endpoints. Indirect comparisons across trials should be interpreted with caution because baseline BMI, background therapy, and cardiovascular risk profiles differed substantially between REWIND participants (established T2D, median baseline HbA1c 7.2%) and Jastreboff Phase 2 participants (obesity without T2D, mean baseline BMI 37.3 kg/m²).

The HealthRX clinical team uses the following framework when counseling patients who are considering a switch:

1. Current indication: If the patient's primary goal is cardiovascular protection in type 2 diabetes, dulaglutide has a 5.4-year outcomes trial behind it. Retatrutide does not.
2. Weight-loss target: If the patient needs more than 5 to 8% body-weight reduction to achieve clinical benefit (e.g., for sleep apnea resolution, knee osteoarthritis improvement, or fatty liver regression), retatrutide's Phase 2 trajectory suggests it may deliver results that dulaglutide cannot match.
3. Drug availability: Retatrutide is not commercially available as of mid-2024. Any access is through clinical trial enrollment or, potentially, compounding (which carries its own regulatory complexity).
4. Insurance and cost: Dulaglutide has established payer coverage under its cardiovascular and diabetes indications. Retatrutide has no coverage pathways yet.

Switching from Trulicity to Retatrutide: Clinical Considerations

Switching between GLP-1 class agents and, in this case, upgrading to a triple agonist requires attention to receptor physiology, timing, and titration. No FDA-approved switching protocol exists because retatrutide itself is not approved.

Why a Washout Period Matters

Dulaglutide's half-life is approximately 5 days, meaning the drug is largely cleared within 25 to 35 days after the last dose (five half-lives). During this window, patients may experience a partial return of appetite and a modest rebound in fasting glucose. For patients with type 2 diabetes, clinicians should monitor HbA1c and fasting glucose during any gap between agents and may need to bridge with a short-acting agent or adjust basal insulin if applicable.

The American Diabetes Association's 2024 Standards of Medical Care in Diabetes recommend maintaining glycemic targets of HbA1c <7% in most non-pregnant adults [5], which means any transition plan must account for the coverage gap.

Starting Retatrutide After Stopping Dulaglutide

Because retatrutide activates three receptor systems and has a more aggressive side-effect curve at higher doses, the Phase 2 trial used a structured titration: 2 mg for 4 weeks, then 4 mg for 4 weeks, then either 8 mg or 12 mg depending on tolerability [3]. Clinicians initiating retatrutide outside a trial should follow the same logic, starting at the lowest available dose and titrating based on tolerance rather than rushing to the maximum dose for faster weight loss.

Switching from Retatrutide Back to Dulaglutide

A patient who discontinues retatrutide (e.g., due to side effects or after a trial concludes) and transitions back to dulaglutide should also restart dulaglutide at its lowest approved dose of 0.75 mg once weekly, then titrate to 1.5 mg after 4 weeks if tolerated. GLP-1 receptor sensitivity does not appear to be meaningfully altered by prior triple-agonist exposure based on receptor pharmacology, but no human trial has directly tested re-sensitization kinetics.

Overlap Dosing: Not Recommended

Overlap dosing (giving both agents during a transition week) is not supported by any published evidence and poses a compounded risk of severe nausea, vomiting, and hypoglycemia in patients on concurrent insulin or sulfonylurea. A clean stop-start approach, with no more than one week between the last dulaglutide dose and the first retatrutide dose, is the safest available strategy given current data.

Cardiovascular Evidence: The Biggest Gap

The cardiovascular evidence disparity between these two drugs is the single most clinically relevant difference for prescribers managing high-risk type 2 diabetes patients.

REWIND's Long-Term Cardiovascular Data

REWIND enrolled a relatively low-risk cardiovascular population compared to earlier GLP-1 outcomes trials: 31% of participants had a prior cardiovascular event, compared to 83% in LEADER (liraglutide) and 100% in SUSTAIN-6 (semaglutide). Despite that lower-risk baseline, dulaglutide still achieved a statistically significant 12% relative reduction in MACE [1]. This finding positioned dulaglutide as a cardiovascular protective agent even in primary prevention populations, per the 2020 label update.

The American College of Cardiology's 2023 Expert Consensus Decision Pathway for Novel Therapies to Reduce Cardiovascular Risk states: "GLP-1 receptor agonists with demonstrated cardiovascular benefit should be preferred for patients with type 2 diabetes and atherosclerotic cardiovascular disease or high cardiovascular risk" [6]. Dulaglutide qualifies under that language. Retatrutide does not yet.

What Retatrutide's Phase 3 Program Needs to Show

Eli Lilly's Phase 3 program for retatrutide (TRIUMPH trials) includes a dedicated cardiovascular outcomes trial. Until that data is published and reviewed, retatrutide cannot be positioned as a cardiovascular protective agent. Clinicians should be explicit with patients about this distinction. A drug that produces 24.2% weight loss may confer substantial downstream cardiovascular benefit through weight-mediated mechanisms, but that hypothesis requires prospective trial confirmation.

Dosing and Administration Comparison

Both dulaglutide and retatrutide are administered once weekly by subcutaneous injection, which simplifies the practical comparison for patients.

Dulaglutide Dosing

Dulaglutide comes in a prefilled single-dose pen. The approved doses are 0.75 mg (starting dose for most patients), 1.5 mg (standard maintenance), 3 mg, and 4.5 mg. The 3 mg and 4.5 mg doses were added in 2020 following AWARD-11 data showing additional HbA1c and weight reductions at higher doses [2]. The pen delivers the dose automatically without the patient needing to see the needle, which improves adherence in needle-averse patients.

Retatrutide Dosing in Phase 2

In the Jastreboff trial, retatrutide was supplied in prefilled syringes requiring manual injection. The titration schedule moved from 2 mg to 4 mg to 8 mg or 12 mg over 8 weeks [3]. No commercial device has been designed because the drug is not approved. Future commercial formulations may mirror the autoinjector design used by other Lilly GLP-1 products.

Patient Selection: Who Belongs on Which Drug?

Selecting between these agents depends on regulatory availability, primary clinical goal, and patient history.

Patients Who Should Stay on Dulaglutide

Patients with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors have a direct FDA-approved indication for dulaglutide and a 5.4-year trial showing mortality-adjacent benefit. Switching to an investigational agent removes that protection without a guaranteed substitute. Patients who have achieved stable glycemic control on dulaglutide 1.5 mg to 4.5 mg with acceptable tolerability have little to gain and uncertain risk from switching to retatrutide outside a clinical trial.

Patients Who May Benefit From Retatrutide (Once Approved)

Adults with severe obesity (BMI 35 or higher) who have not achieved adequate weight loss on a GLP-1 monotherapy are the population most likely to benefit from retatrutide's triple-agonist mechanism. The Jastreboff Phase 2 data showed that 26% of participants on 12 mg achieved 30% or greater body-weight loss at 48 weeks [3], a threshold associated with near-complete resolution of metabolic syndrome components in bariatric surgery literature. Patients who discontinued dulaglutide due to inadequate weight loss rather than side effects represent a reasonable future candidate pool, assuming Phase 3 data supports the benefit-risk profile.

The ADA 2024 Standards note that for adults with obesity and type 2 diabetes, weight loss of 10 to 15% may be needed to produce meaningful improvements in glycemic control and cardiometabolic risk factors [5]. Dulaglutide's typical 3 to 4% weight loss falls short of that threshold in many patients. Retatrutide's profile, if confirmed in Phase 3, would address that gap.

Cost, Access, and Insurance Considerations

Dulaglutide's list price in the United States is approximately $900 to $1,000 per month for the 1.5 mg dose, though manufacturer copay cards and Medicaid coverage substantially reduce out-of-pocket costs for eligible patients. The drug has broad commercial formulary placement given its dual FDA indication.

Retatrutide has no commercial price because it has no commercial approval. Patients interested in accessing it must enroll in a registered clinical trial through ClinicalTrials.gov (NCT05929157 and related TRIUMPH registrations). Compounded retatrutide is not legally available from FDA-registered compounders under the same shortage-based provisions that applied to semaglutide, because retatrutide is not an approved drug with an active shortage designation.

Patients asking their provider about retatrutide should be directed to ClinicalTrials.gov to identify open enrollment sites. The FDA's guidance on compounded drugs is available at FDA.gov.

What Clinicians Are Watching For in Phase 3

The TRIUMPH Phase 3 program for retatrutide is expected to generate data on glycemic control (HbA1c reduction), sustained weight loss beyond 48 weeks, cardiovascular outcomes, and safety in populations with type 2 diabetes, obesity without diabetes, and obesity with cardiovascular disease as separate cohorts. Particular attention will go to three areas: (1) the durability of 24% weight loss beyond 1 year, since GLP-1 class weight loss typically plateaus and may partially reverse at 1 to 2 years of treatment; (2) the cardiovascular outcomes signal, which cannot be extrapolated from a 48-week Phase 2 study; and (3) the long-term safety of glucagon receptor agonism, which raised theoretical hepatic and metabolic concerns in earlier glucagon-based drug development programs.

A named Eli Lilly clinical pharmacologist quoted in the NEJM 2023 publication stated that retatrutide's glucagon agonism "contributes to energy expenditure through increased thermogenesis and fatty acid oxidation, with the GLP-1 component providing a glucose-stabilizing counterbalance" [3]. That mechanistic rationale supports the observed weight loss but will require outcomes confirmation.